NZ747693A - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Info

Publication number
NZ747693A
NZ747693A NZ747693A NZ74769317A NZ747693A NZ 747693 A NZ747693 A NZ 747693A NZ 747693 A NZ747693 A NZ 747693A NZ 74769317 A NZ74769317 A NZ 74769317A NZ 747693 A NZ747693 A NZ 747693A
Authority
NZ
New Zealand
Prior art keywords
derivatives
riboside
nicotinic acid
nicotinamide
ribofuranosyl
Prior art date
Application number
NZ747693A
Other languages
English (en)
Inventor
Troy Rhonemus
Ryan Dellinger
Mark Morris
Aron Erickson
Hadi Cassier
Marie Migaud
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of NZ747693A publication Critical patent/NZ747693A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
NZ747693A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors NZ747693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (1)

Publication Number Publication Date
NZ747693A true NZ747693A (en) 2023-07-28

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ747693A NZ747693A (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN110662542B (zh) 2016-11-11 2025-04-08 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3558312A4 (en) 2016-12-21 2021-01-13 Newsouth Innovations Pty Limited METHODS FOR INCREASING VASCULAR DENSITY
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210196742A1 (en) * 2018-05-22 2021-07-01 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
BR112021016432A2 (pt) 2019-02-21 2021-11-09 Chromadex Inc Composição que compreende prills de cera, processo para produzir prills de cera, composição nutricional, alimento, bebida ou suplemento alimentar que compreende prills de cera, e composição que compreende microesferas encapsuladas
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
WO2020245190A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
WO2020245187A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating or preventing kidney disease
CA3141641A1 (en) * 2019-06-05 2020-12-10 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
US20230000888A1 (en) 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
EP4117678A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230138327A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180739A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections
US20230119002A1 (en) * 2020-03-09 2023-04-20 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN112716969B (zh) * 2021-01-15 2022-11-29 江苏恒正合生命科学有限公司 治疗阿尔茨海默症的组合物及其制备方法、应用
US20240245714A1 (en) * 2021-05-05 2024-07-25 Societe Des Produits Nestle S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso
EP4313067A4 (en) * 2021-06-18 2024-12-18 Mitopower LLC TREATMENT OF IMMUNITY-RELATED DISORDERS, RENAL DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS AND OXIDATIVE STRESS-RELATED DISORDERS USING NRH, NARH AND THEIR REDUCED DERIVATIVES
WO2023076804A1 (en) * 2021-10-27 2023-05-04 Elysium Health Inc. Methods for treatment of menopausal syndromes
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
JP2025505177A (ja) * 2022-02-04 2025-02-21 エリジウム ヘルス インコーポレーテッド リボースリンカーおよびその複合体
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
CA2555675A1 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
MX394291B (es) 2013-10-30 2025-03-24 Chromadex Inc Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
US10280190B2 (en) * 2015-03-16 2019-05-07 Chromadex, Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula

Also Published As

Publication number Publication date
CN109640984A (zh) 2019-04-16
US20170304338A1 (en) 2017-10-26
BR112018071573A2 (pt) 2019-02-12
JP2019514874A (ja) 2019-06-06
CA3021571A1 (en) 2017-10-26
EP3445359B1 (en) 2023-06-07
AU2022221384C1 (en) 2023-08-03
EP3445359A1 (en) 2019-02-27
EP3445359B8 (en) 2023-09-06
MX2018012849A (es) 2019-08-29
AU2017254657A1 (en) 2018-11-15
US10183036B2 (en) 2019-01-22
JP2021176871A (ja) 2021-11-11
JP2023002685A (ja) 2023-01-10
MX393076B (es) 2025-03-24
ZA201807736B (en) 2020-05-27
WO2017184885A8 (en) 2023-08-24
AU2022221384A1 (en) 2022-09-22
JP7493007B2 (ja) 2024-05-30
KR20190008246A (ko) 2019-01-23
ES2948968T3 (es) 2023-09-22
CA3021571C (en) 2023-01-03
EP3445359C0 (en) 2023-06-07
EP3445359A4 (en) 2019-12-25
JP7089480B2 (ja) 2022-06-22
WO2017184885A1 (en) 2017-10-26
AU2022221384B2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
WO2017184885A8 (en) Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+ increasing precursors
MX390185B (es) Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
WO2007061798A3 (en) Nicotinoyl riboside compositions and methods of use
ZA202106912B (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
MX2015005949A (es) Nucleosidos que contienen aza-azucar antiviral.
MX2012000414A (es) Derivados piridin-4-ilo.
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
ATE547098T1 (de) Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt
WO2010123591A3 (en) Small molecule inhibitors of nads, namnat, and nmnat
WO2014082027A3 (en) Antioxidant dietary supplement
TW200607804A (en) Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2010035219A3 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors
PH12014501134B1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
PH12014502823A1 (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX2015008837A (es) Composiciones parenterales estables de dnj.
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
DOP2010000342A (es) Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales
CY1108314T1 (el) Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος
WO2006072809A3 (en) Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
AU2017241626A1 (en) Viable cell compositions, and methods related to same
MX2025001193A (es) Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca
WO2024259359A3 (en) Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
WO2011103586A3 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417